Posts

Posted on

Athlon Acquisition Corp., Sponsored by an Affiliate of Causeway Media Partners, Announces Pricing of Upsized $240 Million Initial Public Offering

PR Newswire

NEW YORK, Jan. 11, 2021 /PRNewswire/ — Athlon Acquisition Corp. (the “Company“) announced today that it priced its initial public offering of 24,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq“) and trade under the ticker symbol “SWETU” beginning January 12, 2021. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11.50 per share. After the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “SWET” and “SWETW,” respectively. The Company expects the offering to be consummated on January 14, 2020.

The Company, sponsored by an affiliate of Causeway Media Partners, is led by Chief Executive Officer Chris Hickey and Chairman Mark Wan. The Company is a blank check company formed for the purpose of effecting a business combination. The Company intends to focus its search for business combination targets in the health, wellness and fitness sectors and the products, devices, applications, and technology driving growth within these verticals.

Jefferies LLC is serving as the sole book runner for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 3,600,000 units at the initial public offering price to cover over-allotments, if any.

The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10002, by telephone: 877-821-7388 or by email: [email protected].

Registration statements relating to these securities became effective on January 11, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the offering filed with the U.S. Securities and Exchange Commission (the “SEC“). Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

 

Cision View original content:http://www.prnewswire.com/news-releases/athlon-acquisition-corp-sponsored-by-an-affiliate-of-causeway-media-partners-announces-pricing-of-upsized-240-million-initial-public-offering-301205852.html

SOURCE Athlon Acquisition Corp.

Posted on

Hitachi Metals Enters Technical Alliance With Teikuro in Surface Treatment Business for Dies in the North American Market

Hitachi Metals Enters Technical Alliance With Teikuro in Surface Treatment Business for Dies in the North American Market

Customers in the North American market will now have access to “TribecTM Kagari” surface treatment services at Teikuro Corporation, Teikuro’s U.S. location.

TOKYO–(BUSINESS WIRE)–
Hitachi Metals, Ltd. (hereinafter “Hitachi Metals”) is pleased to announce that it has entered into a licensing agreement with Teikuro Inc. (hereinafter “Teikuro”) for the technical provision of Hitachi Metals’ high-performance surface treatment TribecTM in order to meet the demand for surface treatment for dies in the North American market.

Surface treatments for coating film on metal surfaces are an effective technology for increasing the strength, durability and sliding performance of dies and automotive engine parts. In recent years, the need for surface treatments to increase the strength and durability of dies has been increasing more than ever to enable support for high-tensile steel sheets.

In its efforts to expand global sales of tool steel in its specialty steels business, Hitachi Metals has strengthened its tool steel solutions sales structure in several ways. These include acquiring U.S. company Diehl Tool Steel, Inc., and making it a consolidated subsidiary; establishing Hitachi Metals (Ningbo) Co., Ltd., in China; enhancing cutting and processing capacity at its plants in Asia; and introducing surface treatment equipment.

Against this backdrop, Hitachi Metals has entered into a licensing agreement with Teikuro for the technical provision of high-function surface treatment TribecTM in order to strengthen its tool steel solutions sales structure in the North American market. Going forward, customers will have access to “TribecTM Kagari” surface treatment services (including film removal) at Teikuro Corporation, Teikuro’s U.S. location in North America.

Specifically, a dedicated coating facility will be installed at Teikuro Corporation’s Springfield Plant in Ohio, United States, and the service will be offered under the name “T-Forte” by Teikuro Corporation. Sales for customers in the United States and Canada are scheduled to begin on March 1, 2021.

Hitachi Metals will continue to expand its customer base and achieve sustainable growth in the global market by strengthening its material technology and product development capabilities, and providing new products, solutions and services that our markets and customers seek.

Corporate Communications Dept.

Hitachi Metals, Ltd.

Masayuki Yoshihara

[email protected]

KEYWORDS: North America United States Asia Pacific China Japan Ohio

INDUSTRY KEYWORDS: Automotive Manufacturing Manufacturing Steel Engineering Chemicals/Plastics

MEDIA:

Logo
Logo
Posted on

Qilian International Holding Group Limited Announces Pricing of Initial Public Offering

Jiuquan, China, Jan. 11, 2021 (GLOBE NEWSWIRE) — Qilian International Holding Group Limited (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced the pricing of its initial public offering (“Offering”) of 5,000,000 ordinary shares at a public offering price of US$5.00 per share. The ordinary shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on January 12, 2021 under the ticker symbol “QLI”.

The Company expects to receive aggregate gross proceeds of US$25 million from this Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 750,000 ordinary shares at the public offering price, less underwriting discounts. The Offering is expected to close on or about January 14, 2021, subject to the satisfaction of customary closing conditions.

Proceeds from the Offering will be used for fixed asset investment in Oxytetracycline API production facilities, construction of an organic-waste treatment facility, fixed asset investment in Heparin Sodium Preparation facilities, and marketing expenses for Gan Di Xin ®.

The Offering is being conducted on a firm commitment basis. Univest Securities, LLC is acting as the representative of the underwriters and lead book-running manager for the Offering. Loop Capital Markets and Alexander Capital L.P. are acting as co-managers for the Offering. Hunter Taubman Fischer & Li LLC acted as counsel to the Company, and Ortoli Rosenstadt LLP acted as counsel to Univest Securities, LLC in connection with the Offering.

A registration statement on Form F-1 relating to the Offering was filed with the Securities and Exchange Commission (“SEC”) (File Number: 333-234460) and was declared effective by the SEC on December 30, 2020.The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the Offering may be obtained from Univest Securities, LLC, by email at [email protected] or standard mail to Univest Securities, LLC, Attn: 375 Park Avenue, 15th Floor, New York, NY 10152. In addition, a copy of the prospectus relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Qilian International Holding Group Limited

Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company’s products are sold in more than 20 provinces in China. For more information, visit the company’s website at http://ir.qlsyy.net.

About Univest Securities, LLC

Registered with FINRA since 1994, Univest Securities, LLC provides a wide variety of financial services to its institutional and retail clients globally including brokerage and execution services, sales and trading, market making, investment banking and advisory, wealth management. It strives to provide clients with value-add service and focuses on building long-term relationship with its clients. For more information, please visit: www.univest.us.


Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

For more information, please contact:

Ascent Investors Relations LLC

Tina Xiao

President

Phone: 917-609-0333
Email: [email protected]



Posted on

SHAREHOLDER ALERT: CLAIMSFILER REMINDS BSX, QS, SPLK, SWI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, Jan. 11, 2021 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:


Boston Scientific Corporation (BSX)


Class Period: 4/24/2019 – 11/16/2020
Lead Plaintiff Motion Deadline: February 2, 2021
SECURITIES FRAUD
To learn more, visit https://www.claimsfiler.com/cases/view-boston-scientific-corporation-securities-litigation-4


Splunk Inc. (SPLK)


Class Period: 10/21/2020 – 12/2/2020
Lead Plaintiff Motion Deadline: February 2, 2021
SECURITIES FRAUD
To learn more, visit https://www.claimsfiler.com/cases/view-splunk-inc-securities-litigation


SolarWinds Corporation (SWI)


Class Period: 2/24/2020 – 12/15/2020
Lead Plaintiff Motion Deadline: March 5, 2021
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nyse-swi/


QuantumScape Corporation (QS)


Class Period: 11/27/2020 – 12/31/2020
Lead Plaintiff Motion Deadline: March 8, 2021
SECURITIES FRAUD
To learn more, visit https://www.claimsfiler.com/cases/view-quantumscape-corporation-securities-litigation

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact us toll-free (844) 367-9658 or visit the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com



Posted on

Realty Income Announces Pricing Of 10.5 Million Share Common Stock Offering

PR Newswire

SAN DIEGO, Jan. 11, 2021 /PRNewswire/ — Realty Income Corporation (Realty Income, NYSE: O), The Monthly Dividend Company®, today announced that a public offering of 10,500,000 shares of the company’s common stock has been priced at a public offering price of $57.05 per share and is expected to close January 14, 2021. Net proceeds from the offering, after underwriting discounts and commissions, but before deducting other offering expenses, will be approximately $582.3 million. The company also granted the underwriters a 30-day option to purchase up to 1,575,000 additional shares of common stock. The joint book-running managers for the offering are BofA Securities, Morgan Stanley, Wells Fargo Securities and Citigroup.

The company intends to use net proceeds from the offering, along with available cash and additional borrowings as necessary, to fund property acquisitions. As of January 8, 2021, the company had entered into agreements or letters of intent to acquire additional U.S. and U.K. properties with an aggregate estimated purchase price of approximately $676.8 million. Moreover, from January 1 through January 8, 2021, the company has acquired properties with an aggregate purchase price of approximately $130.7 million, which, when combined with the properties under agreement or letter of intent as of January 8, 2021, equals an aggregate estimated purchase price of approximately $807.5 million.

Any remaining net proceeds will be used for general corporate purposes and working capital, which may include additional acquisitions, developments or expansions and/or repayment of borrowings under the company’s $3.0 billion revolving credit facility and/or the company’s $1.0 billion commercial paper program. Acquisitions are subject to uncertainties and there can be no assurance that these planned property acquisitions will be completed at the prices or on the timetable or other terms currently contemplated, or at all, or that the company will enter into binding agreements to acquire properties as to which the company has entered into letters of intent.

A prospectus supplement and accompanying prospectus related to the public offering of these securities will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and the accompanying prospectus, when available, may be obtained from BofA Securities, Attn: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001 or email: [email protected]; or Morgan Stanley, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or Wells Fargo Securities, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 326-5897 or email: [email protected]; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, at (800) 831-9146 or email: [email protected].

These securities are offered pursuant to a Registration Statement that has become effective under the Securities Act. These securities are only offered by means of the prospectus supplement related to the offering and the related prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of these securities, in any state or other jurisdiction where, or to any person to whom, the offer, solicitation, or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.


Forward-Looking Statements

Statements in this press release that are not strictly historical, including statements regarding planned acquisitions, are “forward-looking” statements. Forward-looking statements involve known and unknown risks, which may cause the company’s actual future results to differ materially from expected results. These risks include, among others, general economic conditions, domestic and foreign real estate conditions, tenant financial health, the availability of capital to finance planned growth, volatility and uncertainty in the credit markets and broader financial markets, changes in foreign currency exchange rates, property acquisitions and the timing of these acquisitions, charges for property impairments, the effects of the COVID-19 pandemic and the measures taken to limit its impact, the effects of pandemics or global outbreaks of contagious diseases or fear of such outbreaks, the company’s tenants’ ability to adequately manage its properties and fulfill their respective lease obligations to the company, and the outcome of any legal proceedings to which the company is a party, as described in the company’s filings with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as reflections of the company’s current operating plans and estimates. Actual operating results and property acquisitions may differ materially from what is expressed or forecast in this press release. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date these statements were made.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/realty-income-announces-pricing-of-10-5-million-share-common-stock-offering-301205843.html

SOURCE Realty Income Corporation

Posted on

XPeng Inks Strategic Cooperation Agreement with Banks for RMB12.8 Billion Credit Facilities

XPeng Inks Strategic Cooperation Agreement with Banks for RMB12.8 Billion Credit Facilities

GUANGZHOU, China–(BUSINESS WIRE)–
XPeng Inc. (“XPeng” or the “Company”, NYSE: XPEV), a leading Chinese smart electric vehicle (“Smart EV”) company, announced it signed a strategic cooperation agreement with leading domestic banks at a signing ceremony held today in Guangzhou, China, pursuant to which it will secure a credit line of RMB12.8 billion with an extensive range of credit facilities (the “Agreement”).

Under the terms of the Agreement, five domestic commercial banks including the Agricultural Bank of China, the Bank of China, China Construction Bank, China CITIC Bank and Guangzhou Rural Commercial Bank, will provide credit facilities to support the Company’s business operations and expansion of its manufacturing, sales and service capabilities. These facilities will help the Company optimize the efficiency of its cash management, cost control and other corporate functions.

The strategic cooperation with leading banks further diversifies The Company’s funding channels, underscoring its solid business fundamentals and growth prospects.

The Company is developing rapidly following its successful $900 million pre-IPO fundraising and $1.7 billion IPO in August 2020.

  • In December 2020, the Company completed its first public follow-on offering, raising approximately $2.5 billion.
  • In November 2020, the Company’s second manufacturing base broke ground in Guangzhou, making it the first Chinese start-up EV maker with two self-owned factories.
  • XPeng’s physical sales & service network has expanded into 58 cities with 116 retail sales stores and 50 service centers, as of September 30, 2020.
  • The number of XPeng-branded supercharging stations has expanded to 135, covering 50 cities, as of September 30, 2020.
  • Free supercharging services are provided to XPeng customers at 670 supercharging stations across 100 Chinese cities, since the free-to-use supercharging program was launched in September 2020.
  • The Company delivered a total of 27,041 vehicles in 2020 with a fast-growing customer base that has reached over 40,000.
  • The Company’s third production model – a new Smart EV sedan slated for official launch and customer delivery in 2021 – will be equipped with lidar technology, representing a major breakthrough in the mass production deployment of the cutting-edge autonomous driving technology.
  • In December 2020, the Company delivered the first batch of 100 G3 smart SUVs to customers in Norway, representing a milestone for its international business.

“Looking ahead, 2021 presents us with exciting opportunities. We believe the strategic collaboration with these leading financial institutions will enable us to further accelerate growth by building upon our core strengths. With our unwavering commitment to technology innovation and customer services, we look forward to bringing compelling EV experience tailored to our consumers,” said He Xiaopeng, Chairman and CEO of the Company.

About XPeng

XPeng Inc. is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers in China. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrification/electronic architecture. XPeng is headquartered in Guangzhou, China, with offices in Beijing, Shanghai, Silicon Valley, and San Diego. The Company’s Smart EVs are manufactured at plants in Zhaoqing and Zhengzhou, located in Guangdong and Henan provinces, respectively. For more information, please visit https://en.xiaopeng.com.

For Media Enquiries:

Marie Cheung

XPeng Inc.

+852-9750-5170 or +86-1550-7577-546

[email protected]

KEYWORDS: China Asia Pacific

INDUSTRY KEYWORDS: General Automotive Automotive Alternative Vehicles/Fuels

MEDIA:

Posted on

Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant

– Medivir to Receive an Upfront Payment, as Well as Milestone Payments and Royalties

– IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors

PR Newswire

STOCKHOLM, Jan. 12, 2021 /PRNewswire/ — Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences, Inc. (Nasdaq: IGMS), will receive global, exclusive development rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), leading to cell death (apoptosis) in tumor cells. The combination of IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) being developed by IGM, and birinapant has been shown to enhance anti-tumor activity preclinically. Medivir will receive an upfront payment of USD 1 million upon signing the agreement, followed by an additional USD 1.5 million when birinapant is included by IGM in clinical phase I studies. The terms of the agreement furthermore entitle Medivir, should birinapant be successfully developed and approved, to receive milestone payments up to a total of approximately USD 350 million, plus tiered royalties up to mid-teens on net sales.

– “Agreements, such as the one announced today with IGM, continue to be a core component of Medivir’s corporate mission and business model,” said Yilmaz Mahshid, Chief Executive Officer of Medivir. “Today’s announcement further exemplifies our focus and commitment to the development and commercialization of innovative treatments for cancer, and we look forward to IGM’s progress with birinapant in the clinic and beyond.”

– “Based on our in vitro and in vivo models, which have shown remarkable synergy between IGM-8444 and birinapant, we are excited to explore this combination’s potential to deliver superior anti-tumor activity in patients with solid tumors,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “This agreement is part of a broader strategy to realize the full potential of our IgM drug candidates by maintaining control over the timing and development path of the more promising combinations to emerge from our preclinical and clinical work.  We look forward to moving the IGM-8444-birinapant combination into clinical testing to begin validating the significance of targeting DR5 with an IgM antibody in certain combinations and to continuing to explore similar strategic options across our IgM platform.”

In addition to its apoptotic activity, birinapant augments anti-tumor immune system activity. Through this double action, on both tumor cells and cells of the immune system, birinapant has the potential to improve the treatment of several types of cancer when used in combination with other drugs. IGM-8444 is currently being tested in a phase I dose escalation study in patients with solid and hematologic malignancies. DR5 is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and is often expressed on the surface of cancer cells. Subject to regulatory review, IGM hopes to begin the clinical testing of birinapant in combination with IGM-8444 for the treatment of solid cancers later this year. 

Conference call for investors, analysts and the media

Presenters: Yilmaz Mahshid, CEO Medivir, Fredrik Öberg, CSO Medivir and Fred Schwarzer, CEO IGM Biosciences.

Time: Tuesday January 12, 2021, at 15.00 CET

Phone numbers for participants from:

Sweden + 46 8 505 583 74

Europe + 44 33 3300 9031

US +1 833 526 8347

The conference call will also be streamed via a link on the website: www.medivir.com

The presentation will be available on Medivir’s website after completion of the conference.

For further information, please contact:

Dr Yilmaz Mahshid, CEO, Medivir AB, phone: +46 (0)8 5468 3100.

E-mail: [email protected]

Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation.

The information was submitted for publication, through the agency of the contact person set out above, at 23.59 CET on January 11, 2021.

About birinapant

Birinapant is a SMAC mimetic that was acquired from TetraLogic Pharmaceuticals Corporation (TetraLogic) in 2016 and has since then been developed by Medivir. Medivir recently renegotiated the original agreement with TetraLogic so that the compensation Medivir is obliged to pay in connection with a licensing agreement is based on the distribution of actual future revenues to Medivir.

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high.

The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is developing MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug for patients with HCC.

Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. www.medivir.com

IGM Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements relating to IGM’s plans, expectations and forecasts and to future events. Such forward-looking statements include, but are not limited to, the potential of, and expectations regarding, birinapant, IGM’s technology platform and antibody drug candidates including IGM-8444 and the combination of birinapant and IGM-8444, the potential safety and efficacy of the combination of birinapant and IGM-8444, statements regarding IGM’s Phase 1 clinical trial of IGM-8444, IGM’s development strategy for IGM-8444 and plans to begin clinical testing of birinapant in combination with IGM-8444 for the treatment of solid cancers, and statements by the Chief Executive Officers of Medivir and IGM. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including but not limited to: termination of the license agreement; IGM’s ability to  demonstrate the safety and efficacy of IGM-8444 in combination with birinapant; IGM’s ability to successfully and timely advance the combination through preclinical studies and clinical trials; IGM’s ability to enroll patients in its clinical trials; the potential for the results of clinical trials to differ from preclinical or expected results; the risk of significant adverse events, toxicities or other undesirable side effects; IGM’s ability to successfully manufacture and supply its product candidates, including birinapant and IGM-8444, for clinical trials; the risk that all necessary regulatory approvals cannot be obtained; the risk that the potential benefits of the combination do not outweigh their costs; potential delays and disruption resulting from the COVID-19 pandemic and governmental responses to the pandemic, including any future impacts to IGM’s operations, the manufacturing of its product candidates, the progression of its clinical trials, enrollment in its current and future clinical trials and on its collaborations and related efforts; IGM’s early stages of clinical drug development; risks related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; IGM’s ability to obtain additional capital to finance its operations, if needed; uncertainties related to the projections of the size of patient populations suffering from the diseases IGM is targeting; IGM’s ability to obtain, maintain and protect its intellectual property rights; developments relating to IGM’s competitors and its industry, including competing product candidates and therapies; risks related to collaborations with third parties, including the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of any such collaboration; general economic and market conditions; and other risks and uncertainties, including those more fully described in IGM’s filings with the Securities and Exchange Commission (SEC), including IGM’s Annual Report on Form 10-K filed with the SEC on March 26, 2020, IGM’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, IGM’s Current Report on Form 8-K filed with the SEC on December 7, 2020 and in IGM’s future reports to be filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and IGM specifically disclaims any obligation to update any forward-looking statement, except as required by law.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/medivir-enters-into-exclusive-licensing-agreement-with-igm-biosciences-for-birinapant,c3266520

The following files are available for download:

https://mb.cision.com/Main/652/3266520/1358083.pdf

Press release (PDF)

Cision View original content:http://www.prnewswire.com/news-releases/medivir-enters-into-exclusive-licensing-agreement-with-igm-biosciences-for-birinapant-301205829.html

SOURCE Medivir

Posted on

SHAREHOLDER ALERT: WeissLaw LLP Investigates FBL Financial Group, Inc.

PR Newswire

NEW YORK, Jan. 11, 2021 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of FBL Financial Group, Inc. (“FBL Financial” or the “Company”) (NYSE: FFG) in connection with the proposed interested-party acquisition of the Company by Farm Bureau Property & Casualty Insurance Company (“FBPCIC”), an insurance company serving clients in eight Midwest and Western states.  Under the terms of the agreement, the Company’s shareholders will receive $56.00 in cash for each share of FBL Financial common stock that they hold.  FBPCIC and Iowa Farm Bureau Federation, a not-for-profit, grassroots advocacy organization, together control approximately 61% of the Company’s outstanding common stock. 


If you own FBL Financial Group, Inc. shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:


https://www.weisslawllp.com/FFG/


Or please contact:



Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw LLP is investigating whether (i) FBL Financial’s special committee of the board of directors was truly independent and acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $56.00 per-share merger consideration adequately compensates FBL Financial’s shareholders; and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, multiple analysts have set a price target of $65.00 for the Company, $9.00 above the proposed merger consideration.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-fbl-financial-group-inc-301205825.html

SOURCE WeissLaw LLP

Posted on

890 5th Avenue Partners, Inc. Announces Pricing of $250 Million Initial Public Offering

890 5th Avenue Partners, Inc. Announces Pricing of $250 Million Initial Public Offering

NEW YORK–(BUSINESS WIRE)–
890 5th Avenue Partners, Inc. (the “Company”) today announced the pricing of its initial public offering of 25,000,000 units at a price of $10.00 per unit. The units are expected to be listed on the Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “ENFAU” beginning January 12, 2021. Each unit consists of one share of the Company’s common stock and one-third of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Company expects that its common stock and warrants will be listed on Nasdaq under the symbols ”ENFA” and ”ENFAW,” respectively.

The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Company’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although it intends to focus on businesses in the media and entertainment industries.

Cowen and Company, LLC and Craig-Hallum Capital Group LLC are acting as joint book-running managers for the offering. The Company has granted the underwriters a 45-day option to purchase up to 3,750,000 additional units at the initial public offering price to cover over-allotments, if any.

The public offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, email: [email protected], telephone: 833-297-2926; or Craig-Hallum Capital Group LLC, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, Attn: Equity Capital Markets, telephone: 612-334-6300 or by email at [email protected].

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on January 11, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About 890 5th Avenue Partners, Inc.

890 5th Avenue Partners, Inc. a Delaware corporation, is a blank check company newly formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Company’s management team is led by Emiliano Calemzuk, Chief Executive Officer, Michael Del Nin, Chief Operating Officer and Chief Financial Officer, and Adam Rothstein, Executive Chairman.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the anticipated use of the net proceeds thereof. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

890 Fifth Avenue Partners, Inc

Chris Buffone

575 914 6575

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Technology Finance Entertainment Public Relations/Investor Relations Consulting Communications Professional Services Software Other Entertainment Internet

MEDIA:

Logo
Logo
Posted on

Rickard Gustafson appointed President and CEO

PR Newswire

GOTHENBURG, Sweden, Jan. 12, 2021 /PRNewswire/ —  The Board of AB SKF has appointed Rickard Gustafson as new President and CEO. Rickard Gustafson will succeed Alrik Danielson and join SKF during the first half of 2021.

Rickard Gustafson is currently the President and CEO of the SAS Group. Before joining SAS ten years ago, Rickard Gustafson was the CEO of the insurance company Codan/Trygg Hansa and he has held several positions within General Electric. He holds an MSc from the Institute of Technology at Linköping University, Sweden.

Hans Stråberg, Chairman of the Board of AB SKF, says: “After a thorough and robust search process we are greatly pleased that Rickard Gustafson has agreed to join SKF. Rickard Gustafson’s strong and modern leadership, broad international experience and excitement about joining SKF makes him the right person to lead the continued execution of SKF’s strategy and to take SKF to the next level of profitable growth and development.”

Rickard Gustafson, says: “I’m excited and grateful for the opportunity to join SKF, a highly respected company within its industry. SKF has a clearly defined strategic direction, and I look forward to engaging with the organization and further accelerate the ongoing transformation into an even more customer focused, innovative, efficient and sustainable business.”

Hans Stråberg, says: “The Board wishes to thank Alrik Danielson for his significant contributions to SKF’s development during his time as President and CEO.”

Aktiebolaget SKF
(publ)

This is information that AB SKF is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20:00 CET on 11 January 2021.

CONTACT:

For further information, please contact:

PRESS: Theo Kjellberg, Director, Press Relations

tel: 46 31 337 6576, mobile: 46 725-776576, e-mail: [email protected]

INVESTOR RELATIONS: Patrik Stenberg, Head of Investor Relations

Patrik Stenberg, 46 31-337 2104; 46 705-472 104; [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skf/r/rickard-gustafson-appointed-president-and-ceo,c3266387

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/rickard-gustafson-appointed-president-and-ceo-301205823.html

SOURCE SKF